Beryl Drugs Share Price

Beryl Drugs Limited is a small‑cap pharmaceutical company engaged in the manufacturing of bulk drugs, branded and generic formulations, and specialized products like small-volume injectables, eye/ear drops, I.V. fluids, and veterinary medicines. The Beryl Drugs share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.. 

Market sentiment around the Beryl Drugs stock price often mirrors shifts in demand for injectables and veterinary medicines, API pricing, and investor views on the healthcare sector’s growth prospects. Factors such as the pace of new product approvals, competitive intensity, and government policies on drug pricing influence near‑term valuation and earnings forecasts. All these factors must be closely monitored to have an idea about the Beryl Drugs share price movements. 

The Beryl Drugs live share price provides real‑time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and the reaction of investors to corporate announcements and quarterly results. Constant monitoring of Beryl Drugs live price helps observe short‑term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Beryl Drugs share price today helps investors understand real‑time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short‑term performance, identify possible entry or exit points, and respond to news that may affect the company’s valuation. The Beryl Drugs stock price is influenced by the company’s financial health, though its business model relies heavily on therapeutic injectables. Beryl Drugs share price movements are closely tied to the pharmaceutical sector’s performance.  

Beryl Drugs Limited Company Fundamentals 

A. Company Background 

Beryl Drugs Limited was incorporated in 1993. The company’s registered office is located in Indore, Madhya Pradesh, India. Beryl Drugs is a pharmaceutical company engaged in the manufacture of allopathic pharmaceutical preparations. It is recognized as a key player in the manufacturing of bulk drugs and specializes in small-volume injectables in liquid and dry form, eye and ear drops, I.V. fluids, and a range of veterinary medicines. 

B. Product Lines 

• Branded and generic pharmaceutical formulations 

• Bulk drugs (APIs) 

• Small-volume injectables (liquid form) 

• Small-volume injectables (dry powder form) 

• I.V. fluids in polypack and glass bottles 

• Eye drops and ear drops 

• Ayurvedic and herbal products 

• Veterinary products and medicines 

C. Company Revenue Model 

• Primary revenue from manufacturing and sale of branded and generic pharmaceutical preparations. 

• Volume‑driven revenue based on the number of units of formulations produced and sold. 

• Pricing determined by raw material costs and regulatory framework, affecting overall revenue generation. 

• Revenue from sale of bulk drugs and APIs to other pharmaceutical manufacturers. 

• Income from contract manufacturing services and institutional sales. 

• Revenue from veterinary medicines and animal health products. 

• Seasonal variations in demand for certain therapeutic products affecting revenue patterns. 

• Government policy changes under the National Pharmaceutical Pricing Authority (NPPA) influencing revenue stability. 

D. Geographic Presence 

• Headquartered in Indore, Madhya Pradesh, India. 

• Operations focused on the domestic Indian pharmaceutical market. 

• Exports to select international markets, though the majority of revenue is generated from India. 

• Serves customers across multiple states through a distribution network. 

E. Key Milestones 

• 1993 – Incorporated on August 24. 

• 2025 – Reported annual revenue of ₹20.87 crore and net profit of ₹0.58 crore. 

• 2026 – Market leadership in the institutional injectables segment. 

• 2026 – First-mover status in niche unregulated markets for veterinary and generic injectables. 

F. Industry Perspective

Beryl Drugs operates in the pharmaceutical industry. Globally, the pharmaceutical market was valued at approximately USD 1.6 trillion in 2025 and is projected to reach USD 2.3 trillion by 2030, growing at a CAGR of 7.1%. India is the 3rd largest pharmaceutical market by volume and 14th by value. The Indian pharmaceutical market was valued at USD 50 billion in 2024 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 15‑17%. India supplies over 50% of global demand for various vaccines and 40% of generic demand in key markets. Key drivers include rising healthcare expenditure, increasing chronic disease prevalence, and government initiatives such as the Production Linked Incentive (PLI) scheme for pharmaceuticals. The injectables market, a niche segment, is expected to grow at an even faster pace due to the biologics boom. In recent years, India’s pharmaceutical exports have witnessed a boom, growing at a CAGR of around 10% to approximately USD 25‑30 billion annually. Challenges include stringent pricing regulations by the NPPA, intense competition, high regulatory compliance costs (including USFDA approvals), and the need for continuous research and development investments. The domestic injectables market is expected to be a key growth driver for companies like Beryl Drugs, growing at 12‑15% CAGR. 

Beryl Drugs Limited Stock Market Presence: Listings & Index Representation 

Beryl Drugs is listed on the Bombay Stock Exchange (BSE) under the scrip code 524606. The company is not listed on the National Stock Exchange (NSE). The ISIN for the company is INE415H01017. The company forms part of the BSE SmallCap index and the BSE Healthcare index. On the NSE, the company does not currently have a listing, and therefore it is not a constituent of any Nifty indices. Being represented in the BSE SmallCap and Healthcare indices provides a benchmark for investors to compare the company’s performance against other small‑cap companies in the pharmaceutical sector. The inclusion of Beryl Drugs in these indices enhances the visibility of the company’s stock among investors tracking the small‑cap and healthcare segments. However, the company’s absence from the NSE limits its visibility to some institutional investors. 

Beryl Drugs Limited Stock Performance and Share Price History 

The performance and share price history of Beryl Drugs Limited are influenced by a mix of operational, regulatory, and macroeconomic factors. A primary driver is the fluctuation in demand for pharmaceutical products, as any slowdown in key therapeutic segments directly impacts the Beryl Drugs share price. Government policies regarding the National List of Essential Medicines (NLEM) and price caps also play a critical role, often putting pressure on the Beryl Drugs stock price. Conversely, favourable policy moves have historically boosted investor sentiment. 

Another major factor is competition from both established pharmaceutical giants and other small‑cap generic drugmakers, which can alter long‑term growth projections and influence the Beryl Drugs share price. The company’s revenue growth from its injectables portfolio directly impacts revenue visibility. Quarterly financial results, especially net profit and sales figures, cause immediate swings in the Beryl Drugs stock price. Additionally, broader market trends, global API price volatility, and even seasonal disease patterns contribute to volatility. Historically, the Beryl Drugs share price has shown strong positive momentum during the COVID-19 pandemic. 

The 52‑week high of the stock is largely dictated by sentiment shifts. When the company reports strong growth in its injectables business, the Beryl Drugs share price tends to rally toward its 52‑week high. The Beryl Drugs share price reached a 52‑week high of ₹30.00 on the BSE and a 52‑week low of ₹15.92, indicating a wide trading range. The Beryl Drugs share price recorded a strong rally in 2020, delivering a positive annual return of 60.9%, while the subsequent period has seen the Beryl Drugs share price moderate. 

The Beryl Drugs stock price has been particularly responsive to quarterly earnings releases. When the company reported a net profit of ₹0.58 crore on revenue of ₹20.87 crore for the fiscal year ending March 2025, the Beryl Drugs stock price showed a positive reaction. The Beryl Drugs stock price has shown a pattern of strong positive momentum in years when the company’s earnings exceeded expectations. The Beryl Drugs share price has shown a 1‑year return of 13.8% and a 3‑year of 25.1%, outperforming the BSE Healthcare index. The Beryl Drugs share price has shown a 5‑year total return of 34.5%. The Beryl Drugs share price reached its 52‑week high before consolidating, reflecting normal volatility for a pharmaceutical small‑cap. The Beryl Drugs share price has shown a year‑to‑date return of 7.0% as of April 2026. Comprehending these patterns in the Beryl Drugs share price is instrumental for investors. 

Beryl Drugs Limited Investor Relevance and Role in Portfolio 

Beryl Drugs holds a position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on niche injectables and veterinary products. The company’s specialisation in bulk drugs and small‑volume injectables aligns it with investment strategies that value pharmaceutical manufacturing. The Beryl Drugs share price often mirrors how these themes resonate with investor portfolios. 

Institutional stakeholders play a role in Beryl Drugs’s ownership profile. Promoters hold a 27.48% stake. Mutual funds do not hold any stake. Domestic Institutional Investors (DII) hold 0.00%, Foreign Institutional Investors (FII) hold 0.00%. The retail public holds approximately 64.94% as of March 2026. 

Based on data, Beryl Drugs exhibits varying levels of beta and volatility across different time horizons. Based on data, the long‑term beta of Beryl Drugs stands at -0.15 to 0.21, indicating a near-zero to slightly inverse correlation with the broader market. Based on data, the weekly volatility has been stable over the past year. Based on data, the beta coefficient from various sources is 1.00 from Bajaj Finserv, and -0.15 from Yahoo Finance. The Beryl Drugs stock price has shown periods of heightened responsiveness to sector‑specific news and quarterly earnings releases. The Beryl Drugs share price‘s beta reflects that the company’s niche pharmaceutical nature may provide some stability, though the pharma sector remains sensitive to regulatory changes and drug price fluctuations. The Beryl Drugs share price has historically moved on API price announcements. 

Beryl Drugs Limited Sectoral Relevance and Peer Positioning 

The sector relevance of Beryl Drugs is anchored in its role within the broader Indian bulk drugs and generic formulations industry. Competitors in the pharmaceutical segment include companies such as Bal Pharma Ltd, BDH Industries Ltd, Beta Drugs Ltd, Bharat Immunological & Biologicals Corporation Ltd, and Senores Pharmaceuticals Ltd. 

In valuation terms, factors like the Beryl Drugs P/E ratio have shown extreme variations. The mean historical PE Ratio over the last five years is inflated due to low earnings. The current P/E ratio stands at a very elevated 726.67 to 976.9 times, trading at an extreme premium to its peer median range of 47.29x. The Beryl Drugs P/E ratio has increased in 2025 as earnings contracted sharply, while in 2024 and earlier years, it was elevated. The industry P/E ratio is 47.29 times. 

Similarly, the Beryl Drugs EPS narrative has shown variation according to how operational performance aligns with industry demand cycles. Structural gains from expansion in the injectables segment supported directional improvement in earnings per share, while cyclical headwinds from raw material price inflation have moderated EPS momentum. Beryl Drugs earnings have shown a trajectory that responded to both volume growth and margin pressures over the analysed period. Beryl Drugs market cap has fluctuated, currently standing at approximately ₹11-12 crore. 

Over the past few years, the Beryl Drugs market cap has followed a pattern of growth followed by correction. Revenues grew from ₹15.07 crore in FY 2021 to a peak of ₹26.73 crore in FY 2024, but fell to ₹19.1 crore in TTM. Net profit mirrored this, rising from ₹0.88 crore in FY 2021 to ₹0.93 crore in FY 2024, but fell to -₹0.17 crore in a recent quarter. 

The Beryl Drugs earnings over the past ten years has been characterised by a period of growth followed by recent moderation. The Beryl Drugs share price has been influenced by these valuation metrics. The Beryl Drugs stock price continues to be evaluated in the context of its earnings potential and market position in the injectables segment. 

Summary 

Beryl Drugs is a small‑cap pharmaceutical company listed only on the BSE, where the Beryl Drugs share price reflects drug demand cycles, API price fluctuations, and regulatory policies within the pharma sector. Its representation in the BSE SmallCap and Healthcare indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in the injectables segment.